Walden Group Healthcare M&A Blog

  • The Walden Group advises Riverpoint Medical, LLC in its Partnership with Arlington Capital Partners and Helps Guide the Transaction to a Successful Closing

    The Walden Group, Inc. is pleased to announce that Arlington Capital Partners has acquired a majority interest in its client, Riverpoint Medical, LLC. Riverpoint is a major developer and manufacturer of advanced bioabsorbable and non-absorbable sutures; high-strength fiber implantables for sports medicine surgery; patented cordless surgeon...
    Read More
  • FDA Bans Sales of Transvaginal Mesh

    04/23/2019
    The FDA has ordered the two remaining medical device companies, Boston Scientific and Coloplast, selling surgical mesh for the repair of pelvic organ prolapse to stop all sales and distribution in the US. The FDA said the two companies did not demonstrate a reasonable assurance of safety and effectiveness of these devices in their premarket...
    Read More
  • Breakthroughs in Developing Artificial Hearts

    04/23/2019
    Scientists in Israel have printed the world’s first 3D heart made of human tissue and biological molecules. Using tissues from the patient to make a personalized “ink,” a specialized printer was used to produce a working, pumping human heart complete with blood vessels. Because the engineered heart is made of the patient’s own tissues,...
    Read More
  • GE is Shrinking Even Further – Selling Its Biopharma Business to CEO’s Former Company

    04/23/2019
    General Electric is selling its biopharma business to Danaher Corp. for $21.4b. The deal complements Danaher's current biologics workflow solutions. GE’s biopharma business includes process chromatography hardware and consumables, cell culture media, single-use technologies, development instrumentation and consumables, and related services. GE...
    Read More
  • Rapid Growth for Gene Therapy

    04/23/2019
    Large pharmaceutical and diagnostic players companies have been acquiring emerging gene and cell therapy companies with promising drug pipelines or drug approvals, some with limited revenue. In March 2019, Thermo Fisher Scientific agreed to pay $1.7b to acquire Brammer Bio, which offers pre-clinical and analytical development, process...
    Read More
  • Page 1 of 1212345...10...Last »